Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
92 hedge funds and large institutions have $377M invested in Regulus Therapeutics in 2015 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 49 increasing their positions, 11 reducing their positions, and 14 closing their positions.
357% more call options, than puts
Call options by funds: $18.3M | Put options by funds: $4.02M
345% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 11
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
5% more funds holding
Funds holding: 88 → 92 (+4)
32% less capital invested
Capital invested by funds: $555M → $377M (-$178M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17.5M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$6.24M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$4.9M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.69M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.49M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$7.33M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$6.7M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$6.44M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$3.72M |
RGLS Hedge Fund Activity: Q2 2015 in Review
92 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2015, worth a combined $377M — down 32% from $555M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RGLS positions and 14 closed out — a net gain of 4 holders — while 49 added to existing stakes and 11 trimmed.
The largest buyer was State Street, adding an estimated $17.5M. The largest seller was Wellington Management Group, cutting an estimated $7.49M.
- 92 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2015, up from 88 in Q1 2015.
- Funds reported $377M of Regulus Therapeutics stock for Q2 2015, down 32% quarter-over-quarter.
- 18 funds opened new Regulus Therapeutics positions in Q2 2015 and 14 closed out, a net change of +4 holders.
- The largest Regulus Therapeutics buyer in Q2 2015 was State Street, an estimated $17.5M added.
- The largest Regulus Therapeutics seller in Q2 2015 was Wellington Management Group, an estimated $7.49M sold.
Based on aggregated 13F filings for Q2 2015.